Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)



Status:Completed
Conditions:Cardiology, Hematology
Therapuetic Areas:Cardiology / Vascular Diseases, Hematology
Healthy:No
Age Range:18 - Any
Updated:1/6/2019
Start Date:January 2011
End Date:March 2014

Use our guide to learn which trials are right for you!

A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

The purpose of this study is to determine whether anti-von Willebrand factor Nanobody is safe
and effective as adjunctive treatment in patients with acquired thrombotic thrombocytopenic
purpura (TTP). Patients will receive either placebo or anti-von Willebrand factor Nanobody as
adjunctive therapy to plasma exchange.


Inclusion Criteria:

- 18 years of age or older

- Men or women willing to accept an acceptable contraceptive regimen

- Patients with clinical diagnosis of TTP

- Necessitating plasma exchange (one, single PE session prior to randomisation into the
study is allowed)

- Patient accessible to follow-up

- Obtained, signed and dated informed consent

Exclusion Criteria:

- Platelet count greater or equal to 100,000/µL

- Severe active infection indicated by sepsis (requirement for pressors with or without
positive blood cultures)

- Clinical evidence of enteric infection with E.coli 0157 or related organism

- Anti-phospholipid syndrome

- Diagnosis of disseminated intravascular coagulation (DIC)

- Pregnancy or breast-feeding

- Haematopoietic stem cell or bone marrow transplantation-associated thrombotic
microangiopathy

- Known congenital TTP

- Active bleeding or high risk of bleeding

- Uncontrolled arterial hypertension

- Known chronic treatment with anticoagulant treatment that can not be stopped safely

- Severe or life threatening clinical condition other than TTP that would impair
participation in the trial

- Subjects with malignancies resulting in a life expectation of less than 3 months

- Subjects with known or suspected bone marrow carcinosis

- Subjects who cannot comply with study protocol requirements and procedures

- Known hypersensitivity to the active substance or to excipients of the study drug

- Severe liver impairment, corresponding to grade 3 toxicity defined by the CTCAE
(common terminology criteria for adverse events) scale

- Severe chronic renal impairment
We found this trial at
13
sites
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials